Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases
(WorldNews Business)

SAN CARLOS, Calif.--(BUSINESS WIRE)--Sep 22, 2020-- Siolta Therapeutics, a clinical-stage biotech company, announced today it has raised $30M in a series B investment round to support the clinical development of its lead product, STMC-103H. The series B funding involved participation from top-tier investors and venture firms, including series A investors Khosla Ventures and Marc Benioff as well as new investors Seventure (Health for Life Capital Fund), SymBiosis, and Global Brain (Kirin Health Innovation Fund/GB-VII). Siolta`s live biotherapeutic product (LBP) platform is designed to develop microbiome-based medicines and...